Proton Pump Inhibitors in Allergy: Benefits and Risks.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36162802.
- Also identified by DOI 10.1016/j.jaip.2022.09.022 and PMC identifier 9923889.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Proton pump inhibitors (PPIs) are widely prescribed and are indicated for the treatment of several gastrointestinal disorders. Allergists may prescribe PPIs as a result of the coincidence of gastroesophageal reflux disease with asthma or rhinitis, or when gastroesophageal reflux disease presents as chronic cough. Furthermore, long-term, high-dose PPI therapy is a recommended option for managing eosinophilic esophagitis, resulting in histologic remission in approximately 40% of patients. Here, we discuss current recommendations for PPI use, its deescalation, and its side effect profile. We review evidence supporting the epidemiologic link between the use of acid-suppressant medication and the subsequent development of allergic disorders.
Medical subject headings
- Gastroesophageal Reflux
- Eosinophilic Esophagitis
- Asthma
- Gastritis